Fiasp (fast-acting insulin aspart) / Novo Nordisk 
Welcome,         Profile    Billing    Logout  
 7 Diseases   10 Trials   10 Trials   866 News 


«123456789»
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    CopenFast Trial (Room 23; [Board No. 176]) -  Apr 10, 2023 - Abstract #ADA2023ADA_984;    
    These real-world data confirm associations between missed basal and bolus insulin doses and impaired TIR, highlighting a need for digital tools such as smart insulin pens to help individuals manage their diabetes. In pregnant women with type 1 or type 2 diabetes, use of faster aspart resulted in comparable fetal growth and HbA1c with less severe hypoglycemia compared to IAsp.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Late Postprandial Hypoglycemia Is Reduced with Ultrarapid Insulin (Poster Halls B-C; [Board No. 817]) -  Apr 10, 2023 - Abstract #ADA2023ADA_501;    
    Given the importance of BG control, hospitals should work to optimize meal insulin delivery and develop strategies to address bedtime food intake. Postprandial glucometrics and LPH (glucose <70mg/dL 2-5 hours after a meal) were evaluated according to insulin injection time and type: rapid (RI) or ultrarapid analog-Fiasp
  • ||||||||||  Symlin (pramlintide) / AstraZeneca
    A Pilot Study Evaluating an Insulin and Pramlintide Fully Closed-Loop Delivery System (Room 29; [Board No. 60]) -  Apr 10, 2023 - Abstract #ADA2023ADA_120;    
    The mean total insulin used throughout the interventions was 38.2 (23.5) units on the control arm, 31.8 (18.4) and 32.5 (17.5) on the faster aspart 1:8 and 1:10 respectively, and 36.6 (26.9) and 32.2 (23.5) on the insulin aspart 1:8 and 1:10 arms respectively. This pilot study suggests that our fully automated dual-hormone delivery system has the potential to alleviate carbohydrate counting without degrading time in the target range; and it will be investigated in a larger subsequent study.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (clinicaltrials.gov) -  Mar 31, 2023   
    P1,  N=40, Recruiting, 
    This pilot study suggests that our fully automated dual-hormone delivery system has the potential to alleviate carbohydrate counting without degrading time in the target range; and it will be investigated in a larger subsequent study. Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023
  • ||||||||||  Symlin (pramlintide) / AstraZeneca
    Enrollment closed, Trial completion date, Trial primary completion date:  FCL: A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes (clinicaltrials.gov) -  Mar 14, 2023   
    P=N/A,  N=10, Active, not recruiting, 
    Trial completion date: May 2023 --> Nov 2023 | Trial primary completion date: Mar 2023 --> Nov 2023 Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> May 2023 | Trial primary completion date: Aug 2022 --> May 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    ADVANCED HYBRID CLOSE LOOP SYSTEM DURINGATHLETICS HIGH-PERFORMANCE COMPETITION:A CASE REPORT () -  Feb 23, 2023 - Abstract #ATTD2023ATTD_603;    
    Givenadvances in technology, there is little evidence on high-perfor-mance competition and Advanced Hybrid Close Loop System(AHCL) We present the case of a woman with T1DM, user ofAHCL, during Bolivarian Games 2022.Patient female 25 years old, with 17 years of evo-lution of DM1, in treatment with Faster Aspart and Minimed780G for 1.5 year...The use of MiniMed 780g in addition to dia-betes exercise strategies are effective in achieving metabolictargets during high-performance competition. Further research isneeded to generate recommendations.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    FAST-ACTING INSULIN ASPART COMPARED WITHRAPID-ACTING INSULIN ANALOGS IN THEADVANCED HYBRID CLOSED-LOOP SYSTEMIN ADULTS WITH TYPE 1 DIABETES () -  Feb 23, 2023 - Abstract #ATTD2023ATTD_557;    
    Our aim was to evaluate glu-cose control and safety using FA compared with rapid-actinginsulin analogs (insulin lispro, aspart, glulisine) delivered bythe AHCL system in adults with type 1 diabetes (T1D) after 3months of use in real-life clinical practice.A prospective study was perfomed. The use of FA in an AHCL system providesgreater time in range and less time in hyperglycemia, in a safemanner, compared with rapid-acting insulin analogs in adultswith T1D.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date:  Evaluation of the MiniMed (clinicaltrials.gov) -  Jan 23, 2023   
    P=N/A,  N=250, Recruiting, 
    The use of FA in an AHCL system providesgreater time in range and less time in hyperglycemia, in a safemanner, compared with rapid-acting insulin analogs in adultswith T1D. Trial completion date: Jun 2023 --> Nov 2023
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial primary completion date, Real-world evidence, Real-world:  CONNECT 1: A Research Study Looking at How the Use of NovoPen (clinicaltrials.gov) -  Dec 20, 2022   
    P=N/A,  N=227, Enrolling by invitation, 
    Further large-scale studies are needed to validate the outcomes. Trial primary completion date: Feb 2023 --> Mar 2024
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    PHARMACOKINETICS OF INTRAPERITONEAL FIASP DELIVERED BY ULTRASOUND-GUIDED INJECTION (Hall A5) -  Dec 16, 2022 - Abstract #ATTD2023ATTD_355;    
    This novel approach to intraperitoneal drugdelivery in man is safe and useful for characterizing peritonealpharmacokinetics of novel insulins. If they can be stabilized, thebenefit of insulin analogs administered in the intraperitonealspace may allow for full closed-loop insulin delivery.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Journal:  Influence of insulin collection preservatives in postmortem blood: application to a case of insulin aspart suicide. (Pubmed Central) -  Dec 7, 2022   
    During a degradation study implemented to compare 3 preservatives and dry tubes, suitable insulin aspart stability was observed with EDTA and NaF. Given NaF is standard in forensic toxicology for measuring blood alcohol concentrations, the authors suggest its use for blood collection when insulin intoxication is suspected.
  • ||||||||||  Tresiba (insulin degludec) / Novo Nordisk, Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Real-world evidence, Real-world:  CONNECT 1: A Research Study Looking at How the Use of NovoPen (clinicaltrials.gov) -  Nov 14, 2022   
    P=N/A,  N=227, Enrolling by invitation, 
    Frequent blood glucose monitoring and appropriate patient education are vital for success. Trial completion date: Dec 2023 --> Mar 2024
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk, NovoLog (insulin aspart) / Novo Nordisk
    Enrollment closed, Trial primary completion date:  Insulin Fiasp vs. Insulin Novorapid During Pregnancy and Laction in Women With Pre-existing Diabetes (clinicaltrials.gov) -  Oct 26, 2022   
    P3,  N=216, Active, not recruiting, 
    Ultra-rapid acting insulins provided better PPG control compared to RAIAs but their use might result in more infusion set changes. Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Mar 2023
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion, Enrollment change:  An Indian Post Marketing Study of Mealtime Insulin, Fiasp (clinicaltrials.gov) -  Oct 24, 2022   
    P=N/A,  N=42, Completed, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2022 --> Mar 2023 Enrolling by invitation --> Completed | N=300 --> 42
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Journal:  Pharmacological and clinical characteristics of Insulin Faster Aspart (Fiasp®) (Pubmed Central) -  Oct 18, 2022   
    In addition, fast acting aspart insulin allows a more flexible treatment schedule, as it may be administrated at mealtime, immediately before or up to 20 minutes after; this schedule represents an advantage regarding quality of life in patients with diabetes treated with prandial insulin, especially in populations such as children, pregnant women or elderly subjects. The safety and tolerability profiles are comparable to conventional aspart insulin.
  • ||||||||||  ultra-rapid acting insulin (AT247) / Arecor
    Trial completion:  AT247, NovoLog (clinicaltrials.gov) -  Sep 13, 2022   
    P1,  N=24, Completed, 
    Clinical Trial Registry: clinicaltrials.gov; NCT04200313. Active, not recruiting --> Completed
  • ||||||||||  ultra-rapid acting insulin (AT247) / Arecor
    Enrollment closed:  AT247, NovoLog (clinicaltrials.gov) -  Aug 10, 2022   
    P1,  N=24, Active, not recruiting, 
    Recruiting --> Completed | Trial primary completion date: Jul 2022 --> Feb 2022 Recruiting --> Active, not recruiting
  • ||||||||||  Lyumjev (insulin lispro-aabc injection) / Eli Lilly
    Review, Journal:  What is the value of faster acting prandial insulin? Focus on ultra rapid lispro. (Pubmed Central) -  Aug 5, 2022   
    In a head-to-head study with Faster aspart, Aspart and Lispro, URLi was absorbed faster, provided earlier insulin action, and more closely matched physiological glucose response than the other insulins tested...This was achieved without increasing the risk of hypoglycemia. In this review, we focus on the clinical and pharmacological evidence for URLi in the treatment of diabetes and discuss potential benefits and considerations with URLi compared with RAIs.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Retrospective data, Journal:  Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis. (Pubmed Central) -  Jun 25, 2022   
    Total hypoglycaemic episodes (risk ratio [RR], 1.35; 95% CI, 0.55 to 3.31; P=0.51; I2=0%), severe hypoglycaemia (RR, 2.26; 95% CI, 0.77 to 6.66; P=0.14), infusion site reactions (RR, 1.35; 95% CI, 0.63 to 2.93; P=0.77; I2=0%), and treatment-emergent adverse events (RR, 1.13; 95% CI, 0.80 to 1.60; P=0.50; I2=0%) were comparable. FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability.
  • ||||||||||  Fiasp (fast-acting insulin aspart) / Novo Nordisk
    Trial completion date, Trial primary completion date:  A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes (clinicaltrials.gov) -  Jun 24, 2022   
    P1,  N=40, Recruiting, 
    FIAsp use in insulin pump is associated with better post-prandial glycaemic control with no increased hypoglycaemia or glycaemic variability. Trial completion date: May 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023